`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`___________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________
`SAWAI USA, INC. AND SAWAI PHARMACEUTICAL CO., LTD.,
`Petitioners,
`v.
`BIOGEN MA INC.,
`Patent Owner.
`____________________________________________
`IPR2019-00789
`U.S. Patent No. 8,399,514
`____________________________________________
`
`
`
`
`
`BIOGEN EXHIBIT LIST
`
`
`
`Patent Owner’s Exhibit List
`
`Case No. IPR2019-00789
`
`Further to 37 CPR. § 42.63 (6), Patent Owner hereby submits a current listing
`
`of its exhibits. Exhibits 2006-2008, 2010-2012, 2014-2017 are being filed today.
`
`EXHIBIT
`
`DESCRIPTION
`
`Exhibit
`
`200 l
`
`Exhibit
`2002
`
`Exhibit
`2003
`
`Exhibit
`
`2004
`
`.
`.
`EXhlblt
`2005
`
`Press Release, Upsher-Smith’s Parent Company Forms Strategic
`Alliance with Sumitomo Corporation in US Generics Market (Nov.
`13, 2017) (available at https://www.upsher—
`smith.com/wpcontent/uploads/CO—PR—Sumitomo-Strategic-
`Alliance-USLFINAL. . (1
`
`Press Release, Sumitomo Corporation Participates in Generic
`Pharmaceutical Business in the US. (Nov- 13, 2017) (available at
`httpszl/WWW.sumitomocorp.com/en/jp/news/release/ZO1 7/group/20
`1 71 l l3_2)
`
`Summons in a Civil Action on Defendant Sawai USA Inc., Biogen
`Int’l GmbH & Biogen MA Inc. v. Sawai USA, Inc. & Sawai
`Pharmaceutical Co. Ltd., No. 1:17-cv-00875-LPS, Dkt. 5 (D. Del.
`July 5, 2017)
`
`Scheduling Order, Biogen Int ’1 GmbH & Biogen M4 Inc. v. Amneal
`Pharmaceuticals, et al., No. 1:17—00823-LPS, Dkt. 22 (D. Del.
`February 2, 2018)
`
`Transcript of May 14, 2019 teleconference with APJs Sheridan K.
`Snedden, Jennifer M. Chagnon, and Jacqueline T. Harlow, counsel
`for Patent Owner Biogen MA Inc. and counsel for Petitioner Sawai
`USA, Inc- and Sawai Pharmaceutical Co- Ltd.
`
`Exhibit
`2006
`
`Email from Andrew Kellogg, Supervisory Paralegal, Patent Trial
`and Appeal Board, USPTO (June 3, 2019)
`
`Egg)?“
`
`ANDA 210285 Tentative Approval Letter (available at
`https://www.accessdatafda.gov/drugsatfda_docs/appletter/2019/21
`
`02850ri115000TA ltr. D d
`
`Exhibit
`2008
`
`CenterWatch News Online, Sawai Pharmaceutical to acquire
`Upsher-Smith Laboratories U-S. generics business (Apr. 20, 2017)
`(available at https://www.centerwatch.com/news-
`online/20 l 7/04/20/sawai-pharmaceutical—acquire-upsher-smith—
`laboratories-u-s- ; enerics-business/
`
`
`
`
`
`
`
`Patent Owner’s Exhibit List
`
`Case No. IPR2019-00789
`
`EXHIBIT
`
`DESCRIPTION
`
`Exhibit
`
`2009
`
`Exhibit
`
`2010
`
`Exhibit
`
`201 1
`
`Exhibit
`
`20 1 2
`
`Exhibit
`
`201 3
`
`Exhibit
`
`20 14
`
`Exhibit
`
`2015
`
`Exhibit
`
`2016
`
`Exhibit
`
`201 7
`
`
`
`RESER VED
`
`Sawai Pharmaceutical Co., Ltd. Integrated Report 2018 (available
`at https://ssl4.eir—
`.arts.net/doc/4555/ir material for fiscal
`
`15/53096/00. d
`
`Sumitomo Corporation Integrated Report 2018 (available at
`https://www.sumitomocorp.com/—
`/media/Files/hq/ir/report/investors-guide/201 8/integrated-
`2018en. .df?la=en
`
`FY2018 Business Unit IR Meeting (May 28, 2018) (available at
`https://www.sumitomocorp.com/-
`/media/Files/hq/ir/explain/business/en/201 805281RQA_SHIGEN_
`ENG. D df?la=en
`
`RESER VED
`
`Press Release, Upsher-Smith’s Parent Company Completes Stake
`Transfer To Sumitomo Corporation In US Generics Market (Jan.
`5, 2018) (available at https://www.pmewswire.com/news-
`releases/upsher-smiths-parent-company—completes-stake-transfer-
`to-sumitomo-co u oration—in—us- enerics—market—300578294.html
`
`Sumitomo Corporation, Integrated Solution Provider for
`Pharmaceutical Industry “From upstream to downstream”
`(available at
`h D s://www.sumitomoco o .com/en/us/business/case/g ouo/236
`
`Complaint in a Civil Action, Biogen Int’l GmbH & Biogen 114A Inc.
`v. Sawai USA, Inc. & Sawai Pharmaceutical Co. Ltd, No. 1:17-cv-
`
`00875—LPS, Dkt. 1 D. Del. June 30, 2017
`
`Trial Transcript in a Civil Action, Procter & Gamble Pharm., Inc.
`et a]. v. Hoflmann-LaRoche, Inc. et al., No. 06-civ-34 (S.D.N.Y.
`Ma 25, 2006
`
`
`
`
`
`
`
`
`
`Dated: June 14, 2019
`
`
`
`
`
`
`
`Patent Owner’s Exhibit List
`Case No. IPR2019-00789
`
`
`
`
`
`Respectfully submitted,
`
`
`
`By: / Barbara C. McCurdy /
`Barbara C. McCurdy, Reg. No. 32,120
`Finnegan, Henderson, Farabow, Garrett
` & Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`(202) 408-4047
`Counsel for Patent Owner
`
`4
`
`
`
`CERTIFICATE OF SERVICE
`The undersigned hereby certifies that a copy of the foregoing Biogen Exhibit
`
`List and Exhibits 2006-2008, 2010-2012, 2014-2017 were served electronically via
`
`the PTAB electronic filing system and via email on June 14, 2019, in their entirety
`
`on the following:
`
`Brian Sodikoff
`Katten Muchin Rosenman LLP
`525 West Monroe Street
`Chicago, IL 60661-3693
`Telephone: (312) 902-5462
`E-mail: brian.sodikoff@kattenlaw.com
`
`Christopher B. Ferenc
`Katten Muchin Rosenman LLP
`2900 K Street NW
`North Tower - Suite 200
`Washington, DC 20007
`Telephone: (202) 625-3647
`E-mail: Christopher.ferenc@kattenlaw.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Petitioner has agreed to electronic service.
`
`Dated: June 14, 2019
`
`By: / Catherine A. Sadler /
`Catherine A. Sadler
`Case Manager
`
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`
`
`
`